Compass Therapeutics (CMPX) Cash from Operations (2018 - 2026)
Compass Therapeutics (CMPX) posted Cash from Operations of 17269000.0 for Q1 2026, down 30.29% sequentially from 13254000.0 in Q4 2025, and down 30.75% YoY from 24935930.03 in Q1 2025.
Powered by 
Analysis
Compass Therapeutics (CMPX) Cash from Operations (2018 - 2026) Analysis & Trends
Compass Therapeutics has reported Cash from Operations for 9 years, with the latest figure at 17269000.0 in Q1 2026.
- Quarterly Cash from Operations fell 30.75% year-over-year to 17269000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 53204000.0 (down 20.44% YoY) and the FY2025 annual result came in at 49143000.0, down 9.56% from the prior year.
- Cash from Operations declined to 17269000.0 in Q1 2026 per CMPX's latest filing, from 13254000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 4600000.0 in Q2 2022 and troughed at 17269000.0 in Q1 2026.
- A 5-year average of 10941764.71 and a median of 10942000.0 in 2022 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations slumped 216.52% in 2022, then surged 45.88% in 2023.
- Over 5 years, Cash from Operations stood at 10641000.0 in 2022, then declined by 16.1% to 12354000.0 in 2023, then gained by 25.84% to 9162000.0 in 2024, then slumped by 44.66% to 13254000.0 in 2025, then tumbled by 30.29% to 17269000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 17269000.0, 13254000.0, and 10849000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Compass Therapeutics | 443.65 Mn | 443.65 Mn | - | -14.74 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -14.74 Mn |
| Mar 31, 2026 | -17.27 Mn |
| Dec 31, 2025 | -13.25 Mn |
| Sep 30, 2025 | -10.85 Mn |
| Jun 30, 2025 | -11.83 Mn |
| Mar 31, 2025 | -13.21 Mn |
| Dec 31, 2024 | -9.16 Mn |
| Sep 30, 2024 | -11.05 Mn |
| Jun 30, 2024 | -10.75 Mn |
| Mar 31, 2024 | -13.89 Mn |
| Dec 31, 2023 | -12.35 Mn |
| Sep 30, 2023 | -5.92 Mn |
| Jun 30, 2023 | -10.11 Mn |
| Mar 31, 2023 | -12.23 Mn |
| Dec 31, 2022 | -10.64 Mn |
| Sep 30, 2022 | -10.94 Mn |
| Jun 30, 2022 | -4.60 Mn |
| Mar 31, 2022 | -7.94 Mn |
| Dec 31, 2021 | -4.67 Mn |
| Sep 30, 2021 | -3.46 Mn |